NASDAQ:QNRX - Nasdaq - US74907L3006 - ADR - Currency: USD
6.605
-0.16 (-2.42%)
The current stock price of QNRX is 6.605 USD. In the past month the price decreased by -35.48%. In the past year, price decreased by -75.69%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.83 | 342.01B | ||
AMGN | AMGEN INC | 14.32 | 152.57B | ||
GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
REGN | REGENERON PHARMACEUTICALS | 13.32 | 63.70B | ||
ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
NTRA | NATERA INC | N/A | 20.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
BIIB | BIOGEN INC | 7.34 | 17.72B |
Quoin Pharmaceuticals Ltd is a IL-based company operating in Biotechnology industry. Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba IL
CEO: Shai Yarkoni
Employees: 3
Company Website: https://quoinpharma.com/
Investor Relations: https://investors.quoinpharma.com/
Phone: 97299741444
The current stock price of QNRX is 6.605 USD. The price decreased by -2.42% in the last trading session.
The exchange symbol of QUOIN PHARMACEUTICALS LT-ADR is QNRX and it is listed on the Nasdaq exchange.
QNRX stock is listed on the Nasdaq exchange.
8 analysts have analysed QNRX and the average price target is 61.4 USD. This implies a price increase of 829.66% is expected in the next year compared to the current price of 6.605. Check the QUOIN PHARMACEUTICALS LT-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 135.97M USD. This makes QNRX a Micro Cap stock.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 3 employees.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a support level at 6.59 and a resistance level at 7.13. Check the full technical report for a detailed analysis of QNRX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QNRX does not pay a dividend.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2025-05-07.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-30.2).
ChartMill assigns a fundamental rating of 2 / 10 to QNRX. While QNRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -30.2. The EPS decreased by -194.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.05% | ||
ROE | -97.37% | ||
Debt/Equity | 0.32 |
ChartMill assigns a Buy % Consensus number of 83% to QNRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.